Overview
- An FDA Pharmacy Compounding Advisory Committee voted July 23–24 to recommend adding six of seven reviewed peptides — BPC‑157, KPV, MOTS‑c, TB‑500, Epitalon, and Semax — to the Section 503A bulks list so compounding pharmacies could legally prepare them for prescriptions.
- The vote is non‑binding and the FDA will now review the committee record, public comments and agency analyses before any formal rulemaking that could take many months to a year or longer.
- Patient‑safety groups including ECRI, the Institute for Safe Medication Practices, and the Partnership for Safe Medicines warned the evidence on human safety and efficacy is weak and flagged specific risks such as immune reactions, manufacturing impurities, and a possible cancer risk tied to epitalon.
- Critics also raised concerns about conflicts of interest after a recent HHS reshuffle of the advisory panel and noted that some new members have ties to peptide businesses, which opponents say could erode public trust in the process.
- Supporters framed the recommendation as harm reduction that would move patients away from a large online 'research use only' grey market with inconsistent quality, but experts say robust quality controls, standard dosing, clinical trials and monitoring would be needed before routine clinical use.